Decrease of tolerance to, and physical dependence on morphine by, glutamate receptor antagonists

European Journal of Pharmacology

Volumn 332, Issue 3, 1997, Pages 257-262

  González, Paulo ^a   Cabello, Pilar ^a   Germany, Aniza ^a   Norris, Beryl ^a   Contreras, Enrique ^a  

^a UNIVERSITY OF CONCEPCIÓN   (Chile)

Author keywords

CGP 39551 (DL (E) 2 amino 4 methyl 5 phosphonopentanoate carboxy ethylester; Dizocilpine; Ketamine; Morphine dependence; Morphine tolerance

Indexed keywords

2 AMINO 4 METHYL 5 PHOSPHONO 3 PENTENOIC ACID ETHYL ESTER; DIZOCILPINE; GLUTAMATE RECEPTOR ANTAGONIST; KETAMINE; MORPHINE; NALOXONE;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DEPENDENCE; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MORPHINE ADDICTION; MORPHINE TOLERANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; WITHDRAWAL SYNDROME;

2-AMINO-5-PHOSPHONOVALERATE; ANIMALS; DIZOCILPINE MALEATE; DRUG TOLERANCE; EXCITATORY AMINO ACID ANTAGONISTS; KETAMINE; MALE; MICE; MORPHINE; MORPHINE DEPENDENCE; PAIN MEASUREMENT; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 0343683380     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(97)01099-6     Document Type: Article

References (23)

1. Aanonsen L.M., Wilcox G.L. Nociceptive action of excitatory amino acids in the mouse: Effects of spinally administered opioids, phenciclidine and σ agonists. J. Pharmacol. Exp. Ther. 243:1987;9-19.
2. Bell J.A., Beglan C.L. MK-801 blocks the expression but not the development of tolerance to morphine in the isolated cord of neonatal rat. Eur. J. Pharmacol. 294:1995;289-296.
3. Bernardi M., Bertolini A., Szczawinska K., Genedani S. Blockade of the polyamine site of NMDA receptors produces antinociception and enhances the effect of morphine in mice. Eur. J. Pharmacol. 298:1996;51-55.
4. Cox, B.M., 1993. Opioid receptor-G protein interactions: Acute and chronic effects of opioids. In: Herz, A. (Ed.), Opioids I. Springer-Verlag, Berlin, pp. 145-188.
5. Eddy N.B., Leimbach J.D. Synthetic analgesics II dithienylbutenyl and dithienylbutyl amines. J. Pharmacol. Exp. Ther. 107:1953;385-393.
6. G-nitro-L-arginine, attenuate analgesic tolerance to the mu-opioid morphine but not to kappa-opioids. Pain. 56:1994;69-75.
7. Fagg G.E., Olpe H.-R., Pozza M.F., Baud J., Steinmann M., Schmutz M., Portet C., Baumann P., Theolinga K., Bittinger K., Allgeier H., Heckendorn R., Angst C., Brundish D., Dingwall J.G. CGP 37849 and CGP 39551: Novel and potent competitive N-Methyl-D-aspartate receptor antagonist with oral activity. Br. J. Pharmacol. 99:1990;791-797.
8. Gustein H.B., Trujillo K.A. MK-801 inhibits the development of morphine tolerance at spinal sites. Brain Res. 626:1993;332-334.
9. Headley P.M., Grillner S. Excitatory aminoacids and synaptic transmission: The evidence for a physiological function. Trends Pharmacol. Sci. 11:1990;205-211.
10. Kangrga I., Randic M. Outflow of endogenous aspartate and glutamate from the rat spinal dorsal horn in vitro by activation of low-and high-threshold primary afferent fibres. Modulation by μ-opioids. Brain Res. 553:1991;347-352.
11. Lufty K., Hurlbut D.E., Weber E. Blockade of morphine-induced analgesia and tolerance in mice by MK-801. Brain Res. 616:1993;83-88.
12. 2 using microdialysis in conscious rats. Br. J. Pharmacol. 114:1995;1069-1075.
13. Marek P., Ben-Eliyahu S., Gold M., Liebeskind J.C. Excitatory amino acid antagonists (kynurenic acid and MK-801) attenuate the development of morphine tolerance in the rat. Brain Res. 547:1991;77-81.
14. Marquis K.L., Piesla M.J., Muth E.A., Boast C.A. Effect of acute/chronic MK-801 on naloxone-precipitated jumping in morphine dependent mice. Soc. Neurosci. Abstr. 17:1991;331.
15. Mulder, A.H., Schoffelmeer, N.M., 1993. Multiple opioid receptors and presynaptic modulation of neurotransmitter release in the brain. In: Herz, A. (Ed.), Opioids I. Springer-Verlag, Berlin, pp. 125-144.
16. Näsström J., Karlsson U., Post C. Antinociceptive actions of different classes of excitatory aminoacid receptor antagonists in mice. Eur. J. Pharmacol. 212:1992;21-29.
17. Nakanishi S. Molecular diversity of glutamate receptors and implications for brain functions. Science. 258:1992;597-603.
18. Ripley T.L., Little H.J. Effects on ethanol withdrawal hyperexcitability of chronic treatment with a competitive N-methyl-D-aspartate receptor antagonist. J. Pharmacol. Exp. Ther. 272:1995;112-118.
19. Sepúlveda, M.J., Hernández, L., Tucci, S., Rada, P., Contreras, E., 1996. Excitatory Amino Acids in Accumbens Nucleus of the Rat Brain: An In Vivo Study. Proc. of the 18th Annual Meeting of Sociedad de Farmacología de Chile, Santiago, Chile, p. 7.
20. Trujillo K.A., Akil H. Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801. Science. 251:1991;85-87.
21. Tokuyama S., Wakabayashi H., Ho I.K. Direct evidence for a role of glutamate in the expression of the opioid withdrawal syndrome. Eur. J. Pharmacol. 295:1996;123-129.
22. Watkins J.C., Krogsgaard-Larsen P., Honoré T. Structure activity relationships in the development of excitatory amino acid receptor agonists and competitive antagonists. Trends Pharmacol. 11:1990;25-33.
23. Wong C.S., Cheng C.H., Luk H.N., Ho S.T., Tung C.S. Effects of NMDA receptor antagonists on inhibition of morphine tolerance in rats: Binding at μ-opioid receptors. Eur. J. Pharmacol. 297:1996;1-2.